Patient Medicines Helpline

Patient Medicines Helpline - Oxford University Hospitals

Formulary

All medicines are currently included in the Trust's medicines formulary (a list of medicines approved for use within the Trust).

Oxford University Hospitals Formulary

Pharmacies

John Radcliffe Hospital

The dispensary is in the corridor from the main entrance on Level 2 of the John Radcliffe Hospital.

  • Monday to Friday: 8.00am - 5.00pm
  • Saturday and Sunday: 9.00am - 5.00pm
  • Tel: 01865 221502

Churchill

The dispensary is by the East Entrance of the Churchill Hospital (Car Park 4). You do not have to go in to the main building.

  • Monday to Friday: 9.00am - 5.00pm
  • Saturday and Sunday: 9.00am - 5.00pm
  • Tel: 01865 572153

Cancer Satellite Pharmacy

This dispensary is for oncology and haematology patients seen within the Cancer and Haematology Centre. Other patients should attend the main dispensary (above).

The Cancer Satellite Pharmacy is on Level 0 of the Cancer and Haematology Centre at the Churchill Hospital in the same corridor as Radiotherapy, Day Treatment Unit and Cancer Outpatient departments.

The entrance to the Surgery and Diagnostics building is now the main entrance to the Churchill Hospital: to get to the Cancer and Haematology Centre go into the main entrance, walk on past the feature staircase on your right and take a left turn after the lifts.

Continue along the corridor to find the Pharmacy next to the lifts.

  • Monday to Friday 9.00am - 5.00pm
  • Saturday and Sunday closed
  • Tel: 01865 235617

Horton General Hospital

The dispensary is located by the Oxford Road entrance of the Horton General Hospital. Enter through the Outpatient entrance sliding doors and turn right; it is a short distance along on the right hand side.

  • Monday to Friday: 9.00am - 5.00pm
  • Saturday and Sunday: 9.00am - 5.00pm
  • Tel: 01295 229007

Publications

2022

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
Research paper by Advanced Cancer Pharmacist Faouzi Djebbari et al.

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study

2021

B-Cell repopulation after Ocrelizumab in Multiple Sclerosis Patients (4858)

Cefazolin as second line treatment for invasive Methicillin-Susceptible Staphylococcus aureus infection in a UK cohort of patients

Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients

The standards treatment

2020

A pragmatic approach to intravenous anaesthetics and electroencephalographic endpoints for the treatment of refractory and super-refractory status epilepticus in critical care. Seizure: European Journal of Epilepsy 75 (2020) 153-164

Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: Challenges and measurable outcomes

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK)

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review (pdf)

Co-administration of multiple intravenous medicines: Intensive care nurses' views and perspectives

2018

Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU